欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (1): 57-59.

• 临床研究 • 上一篇    下一篇

盐酸奈福泮缓释片药代动力学及生物等效性

王少华, 于宝东, 陈安进, 初晓, 姜新道, 赵美玲, 闫美兴   

  1. 青岛市立医院临床药理基地, 青岛 266011
  • 收稿日期:2000-11-13 修回日期:2001-04-02 出版日期:2002-02-26 发布日期:2020-11-27
  • 通讯作者: 王少华, 女, 主任药师, 硕士研究生导师, 主要从事临床药理及新药研究工作

Pharmacokinetics andbioequivalenceof sustained-released tablet ofnefopam

WANG Shao-Hua, YU Bao-Dong, CHEN An-Jin, CHU Xiao, JIANG Xin-Dao, ZHAO Mei-Ling, YAN Mei-Xing   

  1. Qingdao Municipal Hospital, Qingdao 266011
  • Received:2000-11-13 Revised:2001-04-02 Online:2002-02-26 Published:2020-11-27

摘要: 目的: 验证盐酸奈福泮缓释片的缓释特性并判定其生物等效性。方法: 18 名健康受试者随机分成两组, 采用双周期交叉试验设计, 单剂量、 多剂量连续给药, 用高效液相色谱法测定血药浓度, 以3p97 药代动力学程序求算相关参数。 结果: 单剂量给药的结果表明 :缓释片在给药后 2 ~ 12 h 内血药浓度维持在 20 ~ 40 mg·L-1 之间, cmax 为(45.8 ±15.7) mg·L-1, tpeak 为(3.4 ±0.8) h; 普通片在给药后 0.5 ~ 8 h 内血药浓度维持在 20 mg·L-1 以上,c max 为(72.7 ±26.0) mg·L-1, tpeak 为(1.6 ±0.6) h。两制剂的 AUC 分别为(363.4 ±107.7) 及(374. 8 ±125.7) mg·h·L-1, 平均相对生物利用度为1.02 ±0.25。多剂量给药的结果表明:缓释片和普通片的cmax 分别为(31.5 ±12.7) 及(33.7 ±10.5) mg·L-1, cmin 分别为(13.4±4.4) 及(10.9 ±5.4) mg·L-1, tpeak分别为 (2.6 ±0.6) 及 (1.2 ±0.5) h, FI 分别为0.77±0.26 及 1.04±0.18。结论: 该缓释片具有缓释特征, 两制剂生物利用度 (AUC) 具有等效性。

关键词: 盐酸奈福泮, 缓释片, 高效液相色谱法, 生物等效性

Abstract: AIM: To verify the bioequivalence be-tween sustained-released tablet of nepopam and normal one.METHODS: 18 volunteers were randomly devided into two groups.Double-periodical crossed design was used, and poly-dose of nefopam was administered to 18 volunteers following single-dose after one-week interval. The concentration of nefopam hydrochloride in serum was determinated by HPLC, and the related parameters came out through 3p97 programme. RESULTS: In the single-dose test the drug concentration of sustained-released tablet maitained 2040 mg·L-1 for 10 h, cmax was (45.8 ±15.7) mg·L-1, tpeak was (3.4±0.8) h, and the cor-responding parameters of normal tablet were over 20 mg·L-1 for 7.5 h, (72.7±26.0) mg·L-1, and (1.6 ±0.6) h.The AUC was (363.4 ±107.1) and (374.8 ±125.7) mg·h·L-1 respectively, and F was (1.02 ± 0.25). In the poly-dose test the cmax of sustained-re-leased and normal one was (31.50±12.65) and (33.68 ±10.51) mg·L-1, cmin was (13.4±4.4) and (10.9± 5.4) mg·L-1, tpeak was (2.6 ±0. 6) and (1.22 ± 0.46) h, and FI was (0.77±0.26) and (1.04±0.18) respectively. CONCLUSION: The sustained-released tablet is credible and the two types of tablet are equieffec-tive in AUC.

Key words: nefopam hydrochloride, sustained-re-leased tablet, HPLC, bioequivalence

中图分类号: